(May 12, 2016, 11:18 AM EDT) -- PHILADELPHIA — A Pennsylvania Superior Court appeals panel on May 11 denied Janssen Pharmaceuticals Inc.’s appeal of a $3 million Topamax birth defect verdict, agreeing with the trial court that the claims are not preempted, that there was no comparative negligence and that the $1.5 million future medical expense award was not “shocking” (Kelly Anderson, et al. v. Janssen Pharmaceuticals, Inc., No. 2330 EDA 2014, Pa. Super.)....